Companies in #TCR Therapy
Found 2 companies operating in this sector.
Cellares
PrivateCellares is the first Integrated Development and Manufacturing Organization (IDMO), using an Industry 4.0 approach to mass-manufacture cell therapies. Its Cell Shuttle platform automates and scales the production of CAR-T and other cell therapies, serving clinical and commercial-stage developers.
Scancell Holdings plc (LSE: SCLP) is a clinical-stage immuno-oncology company developing novel cancer vaccines and T-cell receptor (TCR) therapies. Its lead asset, iSCIB1+, is a DNA-based cancer vaccine entering second-half 2026 clinical trials. Plans Nasdaq listing via reverse merger with Neuphoria.